Patent ID: 8226930
Filing Date: 2012-07-24
Classification: A61P,C07K

Abstract:
1. A method of treating Rett syndrome, comprising the step of administering a pharmaceutical composition comprising (i) a human MeCP2 protein or biologically active fragment of said human MeCP2 protein, or a derivative of said protein or fragment, and (ii) a protein transduction domain, wherein the MeCP2 protein is fused to the protein transduction domain, to a subject suffering from Rett syndrome, wherein said fragment comprises at least 150 contiguous amino acids of the MeCP2 protein; and wherein said derivative of said protein or fragment has at least 60% sequence identity with the amino acid sequence of the MeCP2 protein or fragment thereof; and wherein said fragment or said derivative has at least 60% of the biological activity of the naturally occurring MeCP2 protein in a transcription assay which measures the ability of a protein to bind methylated cytosines.